We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Arguments for Using Direct Oral Anticoagulants in Cancer-Related Venous Thromboembolism.
- Authors
Chiorescu, Roxana Mihaela; Mocan, Mihaela; Stoia, Mirela Anca; Barta, Anamaria; Goidescu, Cerasela Mihaela; Chiorescu, Stefan; Farcaş, Anca Daniela
- Abstract
(1) Background: Patients with cancer with a hypercoagulable state present an increased incidence of venous thromboembolism (VTE). Neoplastic patients with concurrent VTE undergoing anticoagulant treatment face a series of issues. (2) The aim of the present paper is to systematically summarize current VTE management in patients with neoplasia and to review the current clinical evidence from meta-analyses of randomized controlled trials and guidelines regarding the administration of direct oral anticoagulants (DOACs) for cancer-associated VTE. (3) Search Strategy: We performed a review on meta-analyses of randomized controlled trials and guidelines in favor of the administration of DOACs in patients with cancer-associated VTE published in the last 6 years in the Medline (PubMed) and Embase databases. (4) Results: 21 meta-analyses, 14 randomized controlled studies comparing DOACs to VKAs and LMWH, and 7 national and international guidelines were identified. We identified five studies that show the antineoplastic effect of DOAC on experimental models. (5) Conclusions: DOACs can be seen as the first choice for VTE treatment in neoplastic patients who have a low risk of bleeding, who do not have severe renal impairment, and who are not undergoing treatments that could interact with DOAC's mechanism of action.
- Subjects
ANTICOAGULANTS; THROMBOEMBOLISM; RANDOMIZED controlled trials; HEMORRHAGE; TUMORS
- Publication
Healthcare (2227-9032), 2021, Vol 9, Issue 10, p1287
- ISSN
2227-9032
- Publication type
Article
- DOI
10.3390/healthcare9101287